Coya Therapeutics Announces Agreement with Dr. Reddy’s Laboratories
Tuesday, March 21, 2023
Coya Therapeutics announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. Under the terms of the Agreement, Coya has been granted an exclusive, royalty-bearing licence to Dr. Reddy’s proposed biosimilar Abatacept for the development and commercialisation of Coya 302 for the treatment of certain neurological diseases for sale in multiple territories including North and South America, the EU, United Kingdom, and Japan.
The Agreement also provides for the licence of Coya 301, Coya’s low dose IL-2 to Dr. Reddy’s to permit the commercialisation by Dr. Reddy’s of Coya 302 in territories not otherwise granted to Coya. With this partnership, both the organisations will strengthen their abilities to deliver this treatment to patients with neurodegenerative diseases, once regulatory approval is granted.
COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underlying certain neurodegenerative diseases.
